Nathan Trinklein

Nathan Trinklein has extensive experience in the biotechnology industry. Nathan is currently the President and Chief Scientific Officer at Rondo Therapeutics since August 2021. Prior to that, they served as the Chief Technology Officer at Teneobio, Inc. from July 2015 to April 2021. At Teneobio, they played a crucial role in establishing the company, leading a team focused on antibody discovery and pre-clinical development. Notably, Teneobio was acquired by Amgen in 2021.

Before joining Teneobio, Nathan was the Managing Director at Panoply Bio from September 2014 to July 2015. Nathan also co-founded and served as the CEO of SwitchGear Genomics from January 2006 to March 2013. Additionally, Nathan has experience working at Stanford University School of Medicine as the Technical Director for the ENCODE Project from February 2004 to April 2006.

Nathan Trinklein holds a Ph.D. in Genetics, which they obtained from Stanford University between 1999 and 2003. Prior to that, from 1995 to 1999, they completed their undergraduate studies at Wake Forest University, earning a Bachelor of Science (B.S.) degree in Biology.